Back to top

Company News For Dec 12, 2017

Read MoreHide Full Article
  • Shares of KMG Chemicals, Inc. (KMG - Free Report) gained 0.3% after reporting first quarter 2018 earnings of $0.83 a share, surpassing the Zacks Consensus Estimate of $0.63
  • Shares of argenx SE (ARGX - Free Report) rallied almost 79% after the company reported positive results from Phase 2 proof-of-concept trial of its drug ARGX-113 used in the treatment of generalized myasthenia gravis
  • Blueprint Medicines Corporation’s (BPMC - Free Report) shares rallied 22.9% after the company reported positive new data from Phase 1 clinical trial of its drug Avapritinib
  • bluebird bio, Inc.’s (BLUE - Free Report) shares surged 17.9% after reporting positive clinical results from Phase 1 multicenter study of LentiGlobin gene therapy used to cure sickle cell disease at the ASH2017


More from Zacks Corporate Summary

You May Like